Clinical trials: Pruritus
Pruritus, Chronic Kidney Diseases
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Rationale: People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy.
- Trial name
- NCT06593392
- Testing
- Difelikefalin
- Where
- 18 sites in China, Greece and 5 more
- Volunteers
- 18 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Confluent and Reticulated Papillomatosis (CARP)
Topical Minocycline for CARP
This proof-of-concept trial evaluates the efficacy, safety, and patient satisfaction of topical minocycline foam (AMZEEQ®) in patients aged 9 and older with confluent and reticulated papillomatosis (CARP).
- Trial name
- NCT07462702
- Testing
- Topical Minocycline Foam FXFM244, Control
- Volunteers
- 35 people
- Sponsor
- Medical University of South Carolina
Primary Sclerosing Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible…
- Trial name
- VISTAS (NCT04663308)
- Testing
- Volixibat
- Where
- 103 sites in United States, Argentina and 12 more
- Volunteers
- 182 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Scabies; Itch, Scabies
Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)
This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial…
- Trial name
- ITCHY (NCT05500326)
- Testing
- Ivermectin Tablets
- Where
- 5 sites in Laos
- Volunteers
- 120 people
- Sponsor
- Murdoch Childrens Research Institute
Epidermolysis Bullosa (EB)
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry.
- Trial name
- NCT07482787
- Testing
- SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Paradigm Therapeutics
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to…
- Trial name
- NCT06553768
- Testing
- Maralixibat
- Where
- 23 sites in United States, Brazil and 8 more
- Volunteers
- 90 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
- Trial name
- POETYK-PsO-Ped (NCT06979453)
- Testing
- Deucravacitinib
- Where
- 132 sites in United States, Argentina and 14 more
- Volunteers
- 366 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis, Eczema
Cardamom and Topical Roseomonas in Atopic Dermatitis
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep…
- Trial name
- NCT06096857
- Testing
- Roseomonas mucosa (RSM2015) and Cardamom seeds
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
ITCH, Atopic Dermatitis
Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical…
- Trial name
- NCT07560618
- Testing
- Roflumilast Cream 0.15%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Integrative Skin Science and Research
Atopic Dermatitis (AD)
Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis
The goal of this clinical trial is to learn if menthol works to relieve pruritus in atopic dermatitis. The primary objectives are to evaluate the safety and clinical efficacy of menthol-containing gloves and foot-covers…
- Trial name
- NCT07693400
- Testing
- menthol-based hand and foot gloves
- Where
- Taiwan
- Volunteers
- 44 people
- Sponsor
- Taiwan Municipal An-Nan Hospital-China Medical University
Burn Injury
Effects of Non-Invasive Vagus Nerve Stimulation in Adolescent Burn Patients
This study will evaluate the effects of non-invasive vagus nerve stimulation in adolescents aged 12 to 18 years who have burn injuries.
- Trial name
- NCT07566923
- Testing
- Non-Invasive Vagus Nerve Stimulation, Conventional Physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Fenerbahce University
Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
In patients with Alagille syndrome (ALGS), the key objectives are to evaluate the tolerability, long-term safety (including possible liver toxicity) and long-term efficacy of Livmarli treatment.
- Trial name
- NCT07290257
- Testing
- Livmarli Oral Product
- Where
- 15 sites in Belgium, France and 6 more
- Volunteers
- 230 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.
- Trial name
- DISCOVER (NCT05590585)
- Testing
- dupilumab, Topical emollient (moisturizer)
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.
- Trial name
- NCT07014007
- Testing
- RV4421B- EV0407
- Where
- Mauritius
- Volunteers
- 105 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Skin Diseases
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with…
- Trial name
- NCT05649098
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Pregnancy Related, Atopic Dermatitis
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during…
- Trial name
- OPERA-1 (NCT06259669)
- Testing
- Ruxolitinib Cream
- Where
- United States
- Volunteers
- 958 people
- Sponsor
- Incyte Corporation
Pregnancy Related, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
- Trial name
- NCT06627335
- Testing
- Ruxolitinib Cream, TCS
- Where
- United States
- Volunteers
- 5,621 people
- Sponsor
- Incyte Corporation
Hemodialysis Patients, Pruritus
Effect of Topically Applied Olive Oil on Pruritus in Hemodialysis Patients: Pretest-posttest Model With Control Group
Pruritus is one of the common symptoms and complaints in hemodialysis patients. The studies reviewed demonstrated that a number of nonpharmacological interventions are effective in relieving pruritus in hemodialysis patients.
- Trial name
- NCT06737484
- Testing
- APPLYING TOPICAL OLIVE OIL
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people
- Sponsor
- Inonu University
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation